Soheilmoghaddam Farhad, Rumble Madeleine, Cooper-White Justin
Tissue Engineering and Microfluidics Laboratory (TEaM), Australian Institute for Bioengineering and Nanotechnology (AIBN), University Of Queensland, St. Lucia, Queensland, Australia 4072.
School of Chemical Engineering, University Of Queensland, St. Lucia, Queensland, Australia 4072.
Chem Rev. 2021 Sep 22;121(18):10792-10864. doi: 10.1021/acs.chemrev.0c01026. Epub 2021 Jul 2.
Many existing clinical treatments are limited in their ability to completely restore decreased or lost tissue and organ function, an unenviable situation only further exacerbated by a globally aging population. As a result, the demand for new medical interventions has increased substantially over the past 20 years, with the burgeoning fields of gene therapy, tissue engineering, and regenerative medicine showing promise to offer solutions for full repair or replacement of damaged or aging tissues. Success in these fields, however, inherently relies on biomaterials that are engendered with the ability to provide the necessary biological cues mimicking native extracellular matrixes that support cell fate. Accelerating the development of such "directive" biomaterials requires a shift in current design practices toward those that enable rapid synthesis and characterization of polymeric materials and the coupling of these processes with techniques that enable similarly rapid quantification and optimization of the interactions between these new material systems and target cells and tissues. This manuscript reviews recent advances in combinatorial and high-throughput (HT) technologies applied to polymeric biomaterial synthesis, fabrication, and chemical, physical, and biological screening with targeted end-point applications in the fields of gene therapy, tissue engineering, and regenerative medicine. Limitations of, and future opportunities for, the further application of these research tools and methodologies are also discussed.
许多现有的临床治疗方法在完全恢复受损或丧失的组织和器官功能方面能力有限,而全球人口老龄化只会使这种令人尴尬的情况进一步恶化。因此,在过去20年里,对新的医学干预措施的需求大幅增加,基因治疗、组织工程和再生医学等新兴领域有望为受损或老化组织的完全修复或替换提供解决方案。然而,这些领域的成功本质上依赖于生物材料,这些生物材料需要具备提供模仿天然细胞外基质的必要生物学信号的能力,以支持细胞命运。加速此类“指导性”生物材料的开发需要将当前的设计实践转向能够实现聚合物材料快速合成和表征,并将这些过程与能够同样快速地对这些新材料系统与靶细胞和组织之间的相互作用进行定量和优化的技术相结合的实践。本文综述了组合和高通量(HT)技术在聚合物生物材料合成、制造以及化学、物理和生物筛选方面的最新进展,这些技术在基因治疗、组织工程和再生医学领域具有针对性的终点应用。还讨论了这些研究工具和方法的局限性以及进一步应用的未来机会。